| 摘要 |
Inhibitors of HCV replication of formula I;
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R* have the meaning defined in the claims.
;The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in the treatment or prophylaxis of HCV. |
| 主权项 |
1. A compound of formula I: or a stereoisomer thereof, wherein: R and R* are each independently —CR1R2R3, C1-4alkylamino, benzylamino, arylamino, aryl optionally substituted with 1 or 2 substituents selected from halo and methyl, hetero C4-7cycloalkyl; wherein
R1 is selected from C1-4alkyl; phenyl optionally substituted with 1, 2 or 3 substituents independently selected from halo, C1-4alkyl, C1-4alkoxy, trifluoromethoxy or 2 substituents on adjacent ring atoms form a 1,3-dioxolane group; benzyl optionally substituted with halo or methoxy; phenylsulfonylmethyl; heteroaryl; heteroarylmethyl; and C3-6cycloalkyl;R2 is selected from hydrogen, hydroxyl, amino, mono- and di-C1-4alkylamino, C1-4alkylcarbonylamino, C1-4alkyloxycarbonylamino, C1-4alkylamino-carbonylamino, piperidin-1-yl or imidazol-1-yl;R3 is hydrogen, or alternatively,R2 and R3 together form an oxo group; orR1 and R3 together form cyclopropyl;provided that when either one of R or R* represents —CH(C6H5)N(CH3)2 then the other cannot be —CH(C6H5)NHC(═O)OCH3; and when R and R* are identical, then R1 is other than phenyl when R2 is hydroxyl, acetylamino, methoxycarbonylamino or tert. butoxycarbonylamino and R3 is hydrogen; and R1 is other than C1-4alkyl when R2 is C1-4alkylcarbonylamino and R3 is hydrogen; or a pharmaceutically acceptable salt thereof. |
